In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update was the news that it has stopped a study of AKT inhibitor ipatasertib as a treatment for first-line ...

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the Top 10 Hot Stocks with the Highest Upside Potential. On June 5, AbCellera Biologics Inc. (NASDAQ:ABCL) reported that it has appointed Dr. Victor ...

The biomedical company announced plans on Monday to bring 1,200 jobs and relocate 300 jobs from Charlotte to Rock Hill.

NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) — via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ ...

The shape of that competition is given physical form at the 2026 BIO International Convention (BIO 2026) in San Diego, California, which runs from June 22 to 25. Taking residence on the exhibition ...

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the ...

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) — via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ ...

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are living with ...

Wang Xuyu, general manager of Sartorius China, addresses a summit held in Shanghai on Thursday as part of a series of events to mark the German company's 30 years of operations in the China market.

NCBiotech uses “biopharma manufacturing” to describe biopharmaceutical and small-molecule pharmaceutical manufacturers, plus manufacturers of industrial enzymes and R&D products With nearly 34,000 ...

Boulder-based Ambrosia Biosciences announced $100 million oversubscribed series B financing to fund clinical trials for its oral small molecule GLP-1 diabetes and weight loss medication. In 2024, the ...